Treatment Free Intervals after Subsequent Chemotherapy Lines in Recurrent Ovarian Cancer ()
ABSTRACT
Aim: Despite recent advances in the treatment of ovarian cancer, recurrence
of the disease is still frequent. This study evaluated whether multiple lines
of chemotherapy have impact on overall survival (OS), progression free survival
(PFS) or on treatment free intervals (TFIs) after serial chemotherapy lines in
recurrent settings. Methods: A total of 189 patients with ovarian cancer (including fallopian tube and
primary peritoneal cancer), who were treated in Kuopio University Hospital in
Finland during 2009-2014, were enrolled. The medical files of these patients
were retrospectively reviewed. Results: Median OS and PFS were significantly higher at the time of the first
relapse compared to subsequent relapses (p < 0.001). TFIs shortened
significantly after the first relapse (p < 0.001). The differences in TFIs
were also seen when comparing platinum sensitive,
semi-sensitive and platinum resistant patients. The total amount of TFI times during the whole follow-up
time was significantly reduced in those patients that received at least
one form of aggressive care at the end of
life (p = 0.004). Conclusions: Ovarian cancer patients received often
multiple lines of chemotherapy. TFIs after
subsequent chemotherapy lines decreased
during the disease course. More efforts should be taken to avoid unnecessary
and ineffective treatments especially in recurrent phase of the disease.
Share and Cite:
Sallinen, H. , Rintanen, V. , Keski-Nisula, L. and Anttila, M. (2021) Treatment Free Intervals after Subsequent Chemotherapy Lines in Recurrent Ovarian Cancer.
Journal of Cancer Therapy,
12, 346-357. doi:
10.4236/jct.2021.126031.